Phase 2 Lymphoma Trial, Recruiting NCT05958719 Sponsor: Institute of Hematology & Blood Diseases Hospital, China Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT05958719
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a specific type of lymphoma called nodal T-follicular helper (TFH) cell lymphoma, confirmed by a tissue sample test.
  • People who are older than 18 years of age.
  • People whose blood counts and organ function meet specific levels — including white blood cells, platelets, liver function, and kidney function — as measured by blood tests (confirm with trial site for exact values).
  • People who are relatively well and able to carry out daily activities, rated on a standard scale from 0 (fully active) to 2 (up and about more than half the day).
  • People whose heart is pumping at 50% efficiency or more, as measured by an ultrasound of the heart.
  • People who are expected to live for more than 3 months.

Who may not be able to join:

  • People who have previously received chemotherapy, radiation therapy, or any other cancer treatment.
  • People whose lymphoma has spread to the brain or spinal cord.
  • People who have uncontrolled heart or blood vessel disease, blood clotting disorders, connective tissue diseases, serious infections, or certain other significant health conditions.
  • People who are pregnant or currently breastfeeding.
  • People who have an HIV infection.
  • People who have had another type of cancer in the past, unless they have been fully cleared of it for 5 or more years — though people who have had certain skin cancers (basal cell or squamous cell carcinoma) or early-stage cervical cancer that has been treated may still be considered eligible (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dehui Zou, Dr., Institute of Hematology & Blood Diseases Hospital, China

Phone: 86-022-23909282

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Registry
ClinicalTrials.gov
Start date
2 March 2023
Est. completion
30 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective Response Rate (ORR); Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov